Search
SOLACI Congress
Day 2

IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock.

solaci
solaci
79
0

 IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock. 

IABP-shock-artigo
Holger Thiele
2012-08-26

Original title: IABP-SHOCK II: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock

Previous article
DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.
Next article
PRAGUE-12: Surgical Atrial Ablation: Follow the one-year results.
solaci
solaci

More articles by this author

ACCESS-EUROPE: 12 months results in percutaneous treatment of mitral insufficiency .

solaci - 0
Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers. Procedural success was high,...

GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.

solaci - 0
Presentation Summary: There is a clear association between hyperglycemia and the development of atherosclerosis. The GRACE sub trial, (from ORIGIN study), evaluated the administration...

GARY: German Aortic Valve Registry.

solaci - 0
Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant...

FAST MI: AMI improved the survival associated with the clinical characteristics changes of patients in the French National Registry.

solaci - 0
Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 2

ACCESS-EUROPE: 12 months results in percutaneous treatment of mitral insufficiency .

Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers....
solaci -
SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 0
Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 0
Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Dr. Carlos Fava - 0
Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 0
Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 0
Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Dr. Carlos Fava - 0
Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

Institutional News

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy